Evoke Pharma
Evoke Pharma, Inc.: A specialty pharmaceutical company developing drugs for GI disorders.
Founded
2007Evoke Pharma, Inc.: A specialty pharmaceutical company developing drugs for GI disorders.
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company founded with a mission to develop and commercialize treatments for gastrointestinal (GI) disorders. The company focuses on addressing unmet medical needs in the GI space, aiming to improve the quality of life for patients suffering from these conditions. Evoke Pharma's flagship product is Gimoti, a nasal spray formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis.
Notable figures affiliated with Evoke Pharma include its leadership team of experienced pharmaceutical executives with extensive backgrounds in the US market. The company has received significant investment and support from various stakeholders in the healthcare sector. Key achievements include the FDA approval of Gimoti, which marked a significant milestone in providing a new treatment option for gastroparesis patients. Overall, Evoke Pharma has made a meaningful impact on the GI therapeutic landscape by offering innovative solutions to previously underserved patient populations.
Companies similar to Evoke Pharma include Tioga Pharmaceuticals, Neurogastrx, Evotec and Satiogen Pharmaceuticals.
Evoke Pharma was founded in 2007.
Evoke Pharma's headquarters is located in Solana Beach, CA, US.
Evoke Pharma's most recent funding round was for $14.4M (USD) in January 2021.
As of Jan 20, 2021, Evoke Pharma has disclosed funding of $28.2M (USD). Undisclosed round amounts are excluded.
Evoke Pharma has 5 employees as of Feb 6, 2024.
Satiogen Pharmaceuticals
